758: Kantoff P, Higano CS. Integration of immunotherapy into the management of advanced prostate cancer. Urol Oncol. 2012 Sep-Oct;30(5 Suppl):S41-7. doi: 10.1016/j.urolonc.2012.06.002. Review. PubMed PMID: 23040162. 759: Kantoff PW, Mohler JL. New developments in the management of prostate cancer. J Natl Compr Canc Netw. 2013 May;11(5 Suppl):653-7. Review. PubMed PMID: 23704236. 760: Kantoff PW, Higano CS, Small EJ, Whitmore JB, Frohlich MW, Schellhammer PF. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst. 2012 Jul 18;104(14):1107-9; author reply 1109-12. doi: 10.1093/jnci/djs279. PubMed PMID: 22825556. 761: Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL, Godfrey WR. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010 Mar 1;28(7):1099-105. doi: 10.1200/JCO.2009.25.0597. Epub 2010 Jan 25. PubMed PMID: 20100959; PubMed Central PMCID: PMC2834462. 762: Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294. PubMed PMID: 20818862.